Search results
Results from the WOW.Com Content Network
QRISK3 (the most recent version of QRISK) is a prediction algorithm for cardiovascular disease (CVD) that uses traditional risk factors (age, systolic blood pressure, smoking status and ratio of total serum cholesterol to high-density lipoprotein cholesterol) together with body mass index, ethnicity, measures of deprivation, family history, chronic kidney disease, rheumatoid arthritis, atrial ...
They recommended selective use of low-to-moderate doses statins in the same adults who have a calculated 10-year cardiovascular disease event risk of 7.5–10% or greater. [22] In people over the age of 70, statins decrease the risk of cardiovascular disease but only in those with a history of heavy cholesterol blockage in their arteries.
The individuals included in the analysis had not previously used statins or lipid-lowering drugs and had no history of cancer. Researchers tracked specific statin drugs and outcomes. The people ...
[33] [34] [35] Rosuvastatin 5 mg and 10 mg are examples of regimens meeting the USPSTF guideline; [32] however, insurers have discretion as to which low- and moderate-dose statin regimens to cover under this requirement, [36] and some only cover other statins. [37] The drug was billed as a "super-statin" during its clinical development; the ...
Among people older than 70, hypercholesterolemia is not a risk factor for being hospitalized with myocardial infarction or angina. [82] There are also increased risks in people older than 85 in the use of statin drugs. [82] Because of this, medications which lower lipid levels should not be routinely used among people with limited life ...
A United States guideline recommends statins in those who have a 12% or greater risk of cardiovascular disease over the next ten years. [166] Niacin , fibrates and CETP Inhibitors , while they may increase HDL cholesterol do not affect the risk of cardiovascular disease in those who are already on statins. [ 167 ]
Like all statins, pravastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver that plays a role in producing cholesterol. [5] Pravastatin was patented in 1980 and approved for medical use in 1989. [6] It is on the World Health Organization's List of Essential Medicines. [7] It is available as a generic medication. [5]
In people aged under 50 years, more men than women have hypertension, [10] and in ages above 50 years the prevalence of hypertension is the same in men and women. [10] In ages above 65 years, more women than men have hypertension. [7] Hypertension becomes more common with age. [5] Hypertension is common in high, medium, and low-income countries.